

References

Module 1

- Chiu YH, Chen LS, Chan CC, et al. Health information system for community-based multiple screening in Keelung, Taiwan (Keelung Community-based Integrated Screening No. 3). *International journal of medical informatics*. 2006; 75(5): 369-83.
- Chen LS, Yen AM, Duffy SW, et al. Computer-aided system of evaluation for population-based all-in-one service screening (CASE-PASS): from study design to outcome analysis with bias adjustment. *Annals of epidemiology*. 2010; 20(10): 786-96.
- Wang PE, Wang TT, Chiu YH, et al. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions? *Journal of medical screening*. 2006; 13 Suppl 1: S54-8.

Module 2

- Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. *The New England journal of medicine*. 2009; 360(13): 1310-9.
- Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *Lancet*. 2007; 369(9576): 1861-8.
- Chien CR, Chen TH. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. *International journal of cancer*. 2008; 122(11): 2594-9.
- Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet*. 1996; 348(9040): 1472-7.
- Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *The American journal of gastroenterology*. 2008; 103(6): 1541-9.
- Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. *Lancet*. 2012; 380(9855): 1778-86.
- Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. *Lancet*. 2007; 369(9574): 1693-702.
- Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet*. 1996; 348(9040): 1467-71.
- Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung

- Project: impact of extended follow-up. Journal of the National Cancer Institute. 2000; 92(16): 1308-16.
- Moss, S. M., H. Cuckle, et al. (2006). "Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial." Lancet.368(9552): 2053-2060.
- Report of the Organizing Committee and Collaborators FM, Falun, Sweden. Breast-cancer screening with mammography in women aged 40-49 years. Swedish Cancer Society and the Swedish National Board of Health and Welfare. International journal of cancer. 1996; 68(6): 693-9.
- Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine. 2009; 360(13): 1320-8.
- Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. The New England journal of medicine. 2012; 366(11): 981-90.
- Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012; 380(9855): 1741-8.
- Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiologic clinics of North America. 2004; 42(5): 793-806, v.
- Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985; 1(8433): 829-32.

Module 3

- Chen THH, Yen MF, Lai MS, Koong, SL, Wang CY, Wong JM, Prevost TC, Duffy SW. Evaluation of a Selective Screening for Colorectal Carcinoma: The Taiwan Multicenter Cancer Screening (TAMCAS) Project. Cancer 1999; 86: 1116-28.
- Chen THH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, Yang PM, Lee HS, Duffy SW. Ultrasound screening and risk factor for death from hepatocellular carcinoma in a high risk group in Taiwan. International Journal of Cancer 2002; 98: 257-261.
- Chen LS, Yen AM, Duffy SW, et al. Computer-aided system of evaluation for population-based all-in-one service screening (CASE-PASS): from study design to outcome analysis with bias adjustment. Annals of epidemiology. 2010; 20(10): 786-96.
- Duffy SW, Tabar L, Chen THH, Holmqvist M, Yen MF, Abdsalah S, Epstein B, Frodis E, Ljungberg E, Hedborg-Melander C, Sundbom A, Tholin M, Wiege M, Akerlund A, Wu HM, Tung TS, Chiu YH, Chiu CP, Huang CC, Smith RA, Rosen M, Stenbeck M, Holmberg L. The impact of organized mammography service screening on breast carcinoma mortality in

- seven Swedish counties. *Cancer*. 2002; 95(3):458-69.
- Koong SL, Yen AMF, Chen THH. Efficacy and Cost-effectiveness of Nation-wide Cervical Cancer Screening in Taiwan. *J Med Screen*. 2006;13 Suppl 1:44-7
- Lai MS, Yen MF, Kuo HS, Koong SL, Chen THH, Duffy SW. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). *International Journal of Cancer* 1998; 78: 21-26.
- The Swedish Organised Service Screening Evaluation Group. Drafting committee: Duffy SW, Tabar L, Chen THH, Smith RA, Holmberg L, Jonsson H, Lenner P, Nystrom L, Tornberg S. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. *Cancer Epidemiology, Biomarkers and Prevention* 2006;15(1):45-51.
- Tabar L, Yen MF, Vitak B, Chen THH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. *Lancet*. 2003; 61(9367):1405-10.
- Tseng CD, Yen AM, Chiu SY, Chen LS, Chen HH, Chang SH. A predictive model for risk of prehypertension and hypertension and expected benefit after population-based life-style modification (KCIS No. 24). *Am J Hypertens* 2012(25):171-179.
- Wu GHM, Chen LS, Chang KJ, Hou MF, Chen HT, Liu TC, et al. Evolution of Breast Cancer Screening in Taiwan. *J Med Screen*. 2006;13 Suppl 1:23-7.
- Wu JC, Anttila A, Yen AM, Hakama M, Saarenmaa I, Sarkeala T, Malila N, Auvinen A, Chiu SY, Chen THH. Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. *Breast Cancer Res Treat*. 2010 Jun;121(3):671-8.

Module 4

- Chen CD, Yen MF, Wang WM, Wong JM, Chen THH. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. *British Journal of Cancer* 2003; 88: 1866-73.
- Chen THH, Duffy SW, Day NE. Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. *Journal of Epidemiology and Biostatistics* 1997; 2: 9-23.
- Chen THH, Duffy SW, Tabar L, Day NE. Markov chain models for progression of breast cancer. Part II: prediction of outcomes for different screening regimes. *Journal of Epidemiology and Biostatistics* 1997; 2: 25-35.
- Chen THH, Yen MF, Lai MS, Koong SL, Wang CY, Wong JM, Prevost TC, Duffy SW. Evaluation of a Selective Screening for Colorectal Carcinoma: The Taiwan Multicenter Cancer Screening (TAMCAS) Project. *Cancer* 1999; 86: 1116-28.

- Chen THH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. *Biometrics* 2000; 56(1): 167-172.
- Chen THH, Yen MF, Shiu MN, Tung TH, and Wu HM. Stochastic model for non-standard case-cohort design. *Statistics in Medicine*. 2004;23:633-647
- Chen HH*, Yen AMF, Tabar L. A Stochastic Model for Calibrating the Survival Benefit of Screen-detected Cancers. *JASA* 2012;107(500):1339-1359.
- Chiu SY, Malila N, Yen AM, Anttila A, Hakama M, Chen HH. Analytical decision model for sample size and effectiveness projections for use in planning a population-based randomised controlled trial of colorectal cancer screening. *J Eval Clin Pract*. 2011 Feb;17(1):123-129. Hsieh HJ, Chen THH, Chang SH. Assessing chronic disease progression using non-homogeneous exponential regression Markov models. *Statistics in Medicine*. 2002; 21: 3369-82.
- Shiu MN, Chen THH. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implication for prevention of oral cancer. *European Journal of Cancer Prevention*. 2004;13:39-45
- Wu HM, Yen MF, Chen THH. SAS macro program for non-homogeneous Markov process in modeling multi-state disease progression. *Computer Methods and Programs in Biomedicine*. 2004;75:95-105.
- Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen HH. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. *Breast Cancer Res Treat*. 2010 Jul;122(2):553-66.
- Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, Kujala P, Ruutu M, Chen HH. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen. *Eur Urol*. 2012 May;61(5):1011-8.
- Wu GH, Auvinen A, Yen AMF, Hakama M, Walter SD, Chen HH*. A Stochastic Model for Survival of Early Prostate Cancer with Adjustments for Leadtime, Length Bias, and Over-detection. *Biom J*. 2012 Jan;54(1):20-44.
- Wu YY, Yen MF, Yu CP, Chen HH*. Individually tailored screening of breast cancer with genes, tumor phenotypes, clinical attributes and conventional risk factors. *Br J Cancer*. 2013 May 14. doi: 10.1038/bjc.2013.202. (Accepted)

Module 5

- Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, Kujala P, Ruutu M, Chen HH. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen. *Eur Urol*. 2012 May;61(5):1011-8.
- Wu GH, Auvinen A, Yen AMF, Hakama M, Walter SD, Chen HH*. A Stochastic Model for

Survival of Early Prostate Cancer with Adjustments for Leadtime, Length Bias, and Over-detection. *Biom J*. 2012 Jan;54(1):20-44.

Chen HH*, Yen AMF, Tabar L. A Stochastic Model for Calibrating the Survival Benefit of Screen-detected Cancers. *JASA* 2012;107(500):1339-1359.

Module 6

Chang JC, Chen THH, Duffy SW, Yen AM, Chen SL. Decision modelling of economic evaluation of intervention programme of breast cancer. *J Eval Clin Pract*. 2010 Dec;16(6):1282-8.

Lin WC, Yen AMF, Chang CM, Chao CH, Chen THH. Computer-aided System for Health Economic Evaluation (CASHEE). *J Eval Clin Pract* 2009; 15(5):797-803